Mohammed Husnia Bedewi, Yismaw Malede Berihun, Fentie Atalay Mulu, Tadesse Tamrat Assefa
School of Pharmacy, College of Health Sciences, Addis Ababa University, P.O.Box:9086, Addis Ababa, Ethiopia.
BMC Res Notes. 2019 Aug 20;12(1):528. doi: 10.1186/s13104-019-4569-5.
This study aimed at assessing the management practice of febrile neutropenia (FN) in pediatric cancer patients at Tikur Anbessa Specialized Hospital (TASH), Ethiopia by reviewing patients' charts from 135 participants retrospectively. Data was entered into Epi-info 7 and exported to SPSS 20 for analysis.
Empiric antibiotics therapy (EAT) was given to all patients in which ceftriaxone with gentamycin constituted of 71.8% followed by ceftriaxone monotherapy. EATs were converted to others in 20 (14.8%) and 2 (1.5%) patients for the first and second times respectively, mainly based on poor clinical response without conducting culture and sensitivity tests. These tests were done only for 13 (9.6%) participants and growth was seen in 5 patients; and definitive therapy was given for 2 patients. ANC value was above 500 cell/mm in 80.7% of patients and 98.5% of study participants were afebrile after completion FN treatment. Most of them (70.4%) were treated for FN and 7 of patients died due to all case mortality. The hospital should not rely mainly only on ceftriaxone with gentamycin as EAT and should do culture and sensitivity test to optimize therapy based on susceptibility result before conversion and modification of therapy in management of FN.
本研究旨在通过回顾135名参与者的病历，评估埃塞俄比亚提库尔·安贝萨专科医院（TASH）儿科癌症患者发热性中性粒细胞减少症（FN）的管理实践。数据录入Epi-info 7并导出到SPSS 20进行分析。
所有患者均接受了经验性抗生素治疗（EAT），其中头孢曲松联合庆大霉素占71.8%，其次是头孢曲松单药治疗。EAT分别在20名（14.8%）和2名（1.5%）患者中首次和第二次转换为其他治疗，主要是基于临床反应不佳且未进行培养和药敏试验。仅对13名（9.6%）参与者进行了这些检测，5名患者培养出细菌；对2名患者进行了确定性治疗。80.7%的患者中性粒细胞绝对值（ANC）高于500个细胞/mm³，98.5%的研究参与者在完成FN治疗后体温恢复正常。大多数患者（70.4%）因FN接受治疗，7名患者因所有病例死亡率死亡。医院在FN管理中不应主要仅依赖头孢曲松联合庆大霉素作为EAT，而应在转换和调整治疗前进行培养和药敏试验，以根据药敏结果优化治疗。
